Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K

Slides:

Advertisements

Similar presentations

Neutron radiation therapy for advanced thyroid cancers Tobias R. Chapman, MD, George E. Laramore, PhD, MD, Stephen R. Bowen, PhD, Peter F. Orio, DO, MS.

Advertisements

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Management of independent motion between multiple targets in lung cancer radiation therapy Feng Liu, PhD, An Tai, PhD, Ergun Ahunbay, PhD, Elizabeth.

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD

Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer Shervin M. Shirvani, MD, Ann.

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution Linda W. Martin, MD, Arlene.

Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy Fady F. Youssef, MS, Parag.

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial Susanne M.

High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian, M.D., Vivian Weinberg, Ph.D.,

Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity.

Hippocampal-sparing and target volume coverage in treating 3 to 10 brain metastases: A comparison of Gamma Knife, single-isocenter VMAT, CyberKnife, and.

Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer Shervin M. Shirvani, MD, Ann.

US radiation oncology practice patterns for posttreatment survivor care Bridget F. Koontz, MD, Rashmi Benda, MD, Jennifer De Los Santos, MD, Karen E.

Prospective Study of Patient-Reported Symptom Burden in Patients With Non–Small- Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy Xin.

Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined- Modality Treatment of Malignant Pleural Mesothelioma Alexander Chi,

Postoperative Proton Therapy in the Management of Stage III Thymoma

Andreas Rimner, MD, Daniel R. Gomez, MD, Abraham J

Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation

Jonathan A. Abelson, MD, James D. Murphy, MD, MS, Ellen A

Safety of differential radiation dosing in lymph node positive necks treated with IMRT Stephen Sozio, MBS, Zorimar Rivera-Núñez, PhD, Omar Mahmoud, MD,

My Path from Hiroshima to Houston

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Dosimetric comparison of 3-dimensional conformal radiation therapy and intensity modulated radiation therapy and impact of setup errors in lower limb.

Influence of Preoperative Radiation Field on Postoperative Leak Rates in Esophageal Cancer Patients after Trimodality Therapy Aditya Juloori, BS, Susan.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

US radiation oncology practice patterns for posttreatment survivor care Bridget F. Koontz, MD, Rashmi Benda, MD, Jennifer De Los Santos, MD, Karen E.

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality.

Jong Ho Cho, MD, Masatsugu Hamaji, MD, Mark S. Allen, MD, Stephen D

Impact of radiotherapy dose on dentition breakdown in head and neck cancer patients Mary P. Walker, DDS, PhD, Brian Wichman, MS, An-Lin Cheng, PhD, James.

Lung Perfusion Imaging Can Risk Stratify Lung Cancer Patients for the Development of Pulmonary Complications after Chemoradiation Isis W. Gayed, MD,

Action Levels on Dose and Anatomic Variation for Adaptive Radiation Therapy Using Daily Offline Plan Evaluation: Preliminary Results Baoshe Zhang, PhD,

Esophageal Cancer Located at the Neck and Upper Thorax Treated with Concurrent Chemoradiation: A Single-Institution Experience Shulian Wang, MD, Zhongxing.

Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective.

Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent.

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection Shalini Garg, MD,

Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Patterns of Cardiac Perfusion Abnormalities After Chemoradiotherapy in Patients with Lung Cancer Isis W. Gayed, MD, H Helen Liu, PhD, Xiong Wei, MD,

Efficacy of fiducial marker-based image-guided radiation therapy in prostate tomotherapy and potential dose coverage improvement using a patient positioning.

ITV-Based Robust Optimization for VMAT Planning of Stereotactic Body Radiation Therapy of Lung Cancer Xiaoying Liang, PhD, Dandan Zheng, PhD, Maria Mamalui-Hunter,

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center

Outcomes After Extrapleural Pneumonectomy and Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma David C. Rice, MB, BCh, Craig.

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Effect of Daily and Every Other Day Stereotactic Body Radiation Therapy Schedules on Treatment-Related Fatigue in Patients With Hepatocellular Carcinoma

Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer Michael D. Hasselle, MD, Daniel.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Burnout and Resiliency in Canadian Oncology Residents: A Nationwide Resident and Program Director Survey Hannah Dahn, MD, Angela McGibbon, MD, David.

Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Liru He, MD, Pamela K. Allen, PhD, Adam.

PD5-2-5: Local therapy of primary diseae improves survival in non-small cell lung cancer metastatic to a single organ - a lesson from brain metastases

Safety considerations for IMRT: Executive summary

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural.

Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma Mitchell Machtay, MD, Rebecca Paulus, BS, Jennifer.

Nicholas Trakul, MD, PhD, Jeremy P

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Association between Systemic Chemotherapy before Chemoradiation and Increased Risk of Treatment-Related Pneumonitis in Esophageal Cancer Patients Treated.

Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas Kripa Guram, BS, Mark Smith,

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

The future of cardiac surgery training: A survival guide

PD6-1-6: Mid-course resimulation for small cell lung cancer patients receiving definitive chemoradiation: sparing of normal lung and esophagus without.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung.

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Presentation transcript:

Reirradiation of thoracic cancers with intensity modulated proton therapy Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K. Allen, PhD, Xiaodong Zhang, PhD, Zhongxing Liao, MD, X. Ronald Zhu, PhD, Daniel Gomez, MD, Steven H. Lin, MD, PhD, Michael Gillin, PhD, Ritsuko Komaki, MD, Stephen Hahn, MD, Joe Y. Chang, MD, PhD Practical Radiation Oncology Volume 8, Issue 1, Pages 58-65 (January 2018) DOI: 10.1016/j.prro.2017.07.002 Copyright © 2017 American Society for Radiation Oncology Terms and Conditions

Figure 1 A representative plan showing a patient’s (A) previous intensity modulated radiation therapy plan (50 Gy in 25 fractions), (B) reirradiation intensity modulated proton therapy plan (60 Gy in 30 fractions), and (C) composite plan. Practical Radiation Oncology 2018 8, 58-65DOI: (10.1016/j.prro.2017.07.002) Copyright © 2017 American Society for Radiation Oncology Terms and Conditions

Figure 2 (A) Freedom from local failure, (B) freedom from locoregional failure, (C), progression-free survival, and (D) overall survival among all patients (solid line), patients who received an equivalent dose in 2-Gy fractions of ≥66 Gy (small dashed line), and patients who received <66 Gy (large dashed line). Practical Radiation Oncology 2018 8, 58-65DOI: (10.1016/j.prro.2017.07.002) Copyright © 2017 American Society for Radiation Oncology Terms and Conditions